Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Last trade$146.72
Day change+$1.43 (+0.98%)
Day range$141.56 – $148.57
Volume775,978
Market cap$10.08B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.08B
Price / earnings
23.5×
Price / book
6.38×
Price / sales
3.16×
EV / sales
3.28×
EV / EBITDA
15.08×
Profitability
Earnings per share
$6.18
Return on assets
12.56%
Return on equity
27.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.61×
Current ratio
2.51×
Quick ratio
1.83×
Cash ratio
0.72×
Cash flow
Price / cash flow
19.8×
Price / free cash flow
39.65×
Free cash flow
$254.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PODD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$842M
$801.7M
$761.7M
$783.8M
$706.3M
$649.1M
$569M
$597.5M
Cost of revenue
$209.9M
$239.1M
$232.7M
$215.2M
$196.2M
$196.9M
$159.9M
$166.6M
Gross profit
$632.1M
$562.6M
$529M
$568.6M
$510.1M
$452.2M
$409.1M
$430.9M
Selling, general and administrative
$350.7M
$344.8M
$317.2M
$331.4M
$315.2M
$257.7M
$260.7M
$261M
Research and development
$91.6M
$88.1M
$89.7M
$90.9M
$77.2M
$73.4M
$59.6M
$60.6M
Total operating expenses
$442.3M
$432.9M
$406.9M
$422.3M
$392.4M
$331.1M
$320.3M
$321.6M
Operating income
$189.8M
$129.7M
$122.1M
$146.3M
$117.7M
$121.1M
$88.8M
$109.3M
Interest expense
-$16.2M
-$13.5M
-$14.7M
-$14.9M
-$15.6M
-$19.6M
-$9.2M
-$8.6M
Income before taxes
$177.2M
$118.7M
$113M
$140.2M
$122.8M
$28.4M
$48.2M
$111.4M
Income taxes
$36.1M
$23.7M
$21.9M
$38.6M
$35.2M
$5.9M
$12.7M
$10.7M
Net income
$141.1M
$95M
$91.1M
$101.6M
$87.6M
$22.5M
$35.5M
$100.7M
Net income attributable to common shareholders
$141.1M
$95M
$91.1M
$101.6M
$87.6M
$22.5M
$35.4M
$100.7M
EBITDA
$218M
$156.4M
$148.3M
$170.7M
$139.7M
$143.4M
$110.5M
$130.8M
Basic earnings per share
$2.03
$1.37
$1.30
$1.44
$1.24
$0.32
$0.50
$1.44
Diluted earnings per share
$2.03
$1.37
$1.30
$1.41
$1.24
$0.32
$0.50
$1.36
Recent news
Company coverage with links to the original publishers.
Abbott reported strong mid-to-high-teens EP sales growth globally and over 20% in the U.S., driven by accelerating Volt PFA catheter adoption following its August launch. The company received FDA approval for TactiFlex Duo and CE Mark for Amulet 360, expanding treatment options. However, LAA market weakness is creating headwinds as customers delay purchases awaiting the new Amulet 360 device. Abbott expects Japan's Q4 Volt launch to provide growth momentum.
Insulet Corporation (PODD), a manufacturer of continuous insulin delivery systems, has been highlighted as a top growth investment opportunity. The company holds a Zacks Rank #2 (Buy) rating with a VGM Score of B and Growth Style Score of B, forecasting 36% year-over-year earnings growth for the current fiscal year. Eight analysts revised earnings estimates upward in the last 60 days, with the consensus estimate increasing to $6.76 per share for fiscal 2026.
Insulet (PODD) is recommended as a growth stock with a Zacks Growth Score of B and Zacks Rank #2 (Buy). The company demonstrates strong fundamentals including 35.3% projected EPS growth (vs. 9.1% industry average), 42.9% year-over-year cash flow growth (vs. -2.1% industry average), and positive earnings estimate revisions of 3.7% over the past month.
Insulet is expected to report Q3 2026 earnings on November 4 with consensus EPS of $1.59 (+28.2% YoY) and revenues of $833.3 million (+18% YoY). However, recent analyst revisions suggest bearish sentiment with a negative Earnings ESP of -1.86%, making an earnings beat unlikely despite the company's strong historical track record of beating estimates.
The global digital health and remote patient monitoring market is projected to grow from $26.8 billion in 2025 to $80.8 billion by 2031, expanding at a 20.2% CAGR. Growth is driven by rising chronic disease management demand, expanding reimbursement coverage, and maturing wearable sensor technology, enabling a shift from episodic facility-centered care to continuous connected care models.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.